{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:33:54Z","timestamp":1792794834562,"version":"4.5.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"LMU Hospital Munich"},{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Thomas Kirch Foundation"},{"name":"Nuclear Medicine and Neuro-Oncology","id":[{"id":"https:\/\/ror.org\/05ghs6f64","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ESMO Translational Research Fellowship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Improved prognostic stratification, including imaging-based parameters, is needed to guide treatment decisions in IDH-mutant glioma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this bicentric retrospective study, 457 patients with IDH-mutant glioma and [18F]fluoroethyltyrosine or [11C]methionine positron emission tomography (PET) prior to radiotherapy or systemic treatment were included. Associations of maximum and mean tumor-to-background ratios (TBRmax\/TBRmean) and PET-positive volume (PET volume) with time to next intervention (TTNI) and overall survival (OS) were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 251 (54.9%) patients with astrocytoma and 206 (45.1%) with oligodendroglioma were included. In patients with astrocytoma who underwent PET before resection, measurable disease according to PET RANO 1.0 criteria was associated with shorter TTNI compared to no\/non-measurable disease (median 46.0 vs. 67.9 months; P\u2005=\u2005.004). Univariable analysis showed an association of TTNI with TBRmax, TBRmean, and PET volume in astrocytoma and PET volume in oligodendroglioma. Multivariable analyses including age, WHO grade, extent of resection, postoperative treatment, and magnetic resonance imaging (MRI)-based tumor extent indicated an association of TTNI with TBRmax (HR 1.48 [95%CI: 1.09\u20132.01]) and TBRmean (HR 1.93 [95%CI: 1.14\u20133.27]) in astrocytoma and PET volume (HR [10\u00a0ml increase]: 1.18 [95%CI: 1.03\u20131.36]) in oligodendroglioma. In astrocytoma, also OS was related to TBRmax (HR: 1.40 [95%CI: 1.13\u20131.74]), TBRmean (HR: 1.97 [95%CI: 1.21\u20133.22]), and PET volume (HR: 1.23 [95%CI: 1.10\u20131.37]) in univariable analysis. Further analyses considering timepoint of PET showed consistent results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this retrospective study, amino acid PET parameters were associated with outcome in newly diagnosed IDH-mutant glioma. Future clinical trials should include PET imaging to define imaging-based prognostic signatures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noaf196","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T11:54:14Z","timestamp":1755690854000},"page":"3292-3305","source":"Crossref","is-referenced-by-count":10,"title":["Prognostic stratification of newly diagnosed\n                    <i>IDH-<\/i>\n                    mutant gliomas by [18F]fluoroethyltyrosine and [11C]methionine PET: A retrospective, bicentric cohort study"],"prefix":"10.1093","volume":"27","author":[{"given":"Maximilian J","family":"Mair","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna , Vienna ,","place":["Austria"]},{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7147-4594","authenticated-orcid":false,"given":"Jan-Michael","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne , Cologne ,","place":["Germany"]},{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, LMU University Hospital, LMU Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enio","family":"Barci","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Katzendobler","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, LMU University Hospital, LMU Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jera","family":"Isakaj","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luzia","family":"Berchtold","sequence":"additional","affiliation":[{"name":"Institute of Medical Statistics, Center for Medical Data Science, Medical University of Vienna , Vienna ,","place":["Austria"]},{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thedora","family":"Aras","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"St\u00fcrzl","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Hennenberg","sequence":"additional","affiliation":[{"name":"Division of Neuroradiology and Musculoskeletal Radiology, Department of Radiology and Image-guided Therapy, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Reis","sequence":"additional","affiliation":[{"name":"Institute of Neuroradiology, LMU University Hospital, LMU Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah C","family":"Puhr","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schabh\u00fcttl","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna , Vienna ,","place":["Austria"]},{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-9831","authenticated-orcid":false,"given":"Barbara","family":"Kiesel","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6014-0273","authenticated-orcid":false,"given":"Georg","family":"Widhalm","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelheid","family":"W\u00f6hrer","sequence":"additional","affiliation":[{"name":"Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Nakuz","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Department of Radiology and Image-guided Therapy, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hacker","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Department of Radiology and Image-guided Therapy, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8258-3681","authenticated-orcid":false,"given":"Julia","family":"Furtner","sequence":"additional","affiliation":[{"name":"Research Center for Medical Image Analysis and Artificial Intelligence (MIAAI), Faculty of Medicine and Dentistry, Danube Private University , Krems ,","place":["Austria"]},{"name":"Division of Neuroradiology and Musculoskeletal Radiology, Department of Radiology and Image-guided Therapy, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Sch\u00f6necker","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, LMU University Hospital, LMU Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick N","family":"Harter","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK) , Partner Site Munich, Munich ,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF) , Partner Site Munich, Munich ,","place":["Germany"]},{"name":"Center of Neuropathology and Prion Research, Faculty of Medicine, LMU Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6634-0927","authenticated-orcid":false,"given":"Louisa","family":"von Baumgarten","sequence":"additional","affiliation":[{"name":"Department of Neurology, LMU University Hospital, LMU Munich , Munich ,","place":["Germany"]},{"name":"German Cancer Consortium (DKTK) , Partner Site Munich, Munich ,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF) , Partner Site Munich, Munich ,","place":["Germany"]},{"name":"Department of Neurosurgery, LMU University Hospital, LMU Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S","family":"Berghoff","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Thon","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Knappschaft University Hospital Bochum , Bochum ,","place":["Germany"]},{"name":"Department of Neurosurgery, LMU University Hospital, LMU Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0953-7624","authenticated-orcid":false,"given":"Nathalie L","family":"Albert","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK) , Partner Site Munich, Munich ,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF) , Partner Site Munich, Munich ,","place":["Germany"]},{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"2026021901464894500_CIT0001","doi-asserted-by":"crossref","first-page":"102124","DOI":"10.1016\/j.ctrv.2020.102124","article-title":"A basic review on systemic treatment options in WHO grade II-III gliomas","volume":"92","author":"Mair","year":"2021","journal-title":"Cancer Treat Rev."},{"issue":"6","key":"2026021901464894500_CIT0002","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(17)30194-8","article-title":"European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"issue":"9","key":"2026021901464894500_CIT0003","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1200\/JCO.2014.56.9079","article-title":"Health-related quality of life in stable, long-term survivors of low-grade glioma","volume":"33","author":"Boele","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026021901464894500_CIT0004","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1474-4422(09)70204-2","article-title":"Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up","volume":"8","author":"Douw","year":"2009","journal-title":"Lancet Neurol"},{"issue":"8","key":"2026021901464894500_CIT0005","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1200\/JCO.2002.08.121","article-title":"Prognostic factors for survival in adult patients with cerebral low-grade glioma","volume":"20","author":"Pignatti","year":"2002","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026021901464894500_CIT0006","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/neuonc\/noae107","article-title":"The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors","volume":"26","author":"Van Den Bent","year":"2024","journal-title":"Neuro-Oncology."},{"issue":"7","key":"2026021901464894500_CIT0007","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med."},{"issue":"11","key":"2026021901464894500_CIT0008","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3174\/ajnr.A4407","article-title":"Patterns of tumor contrast enhancement predict the prognosis of anaplastic gliomas withIDH1Mutation","volume":"36","author":"Wang","year":"2015","journal-title":"AJNR Am J Neuroradiol."},{"key":"2026021901464894500_CIT0009","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejca.2018.10.019","article-title":"Contrast enhancement is a prognostic factor in IDH1\/2 mutant, but not in wild-type WHO grade II\/III glioma as confirmed by machine learning","volume":"107","author":"Suchorska","year":"2019","journal-title":"Eur J Cancer"},{"issue":"11","key":"2026021901464894500_CIT0010","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1200\/JCO.21.02929","article-title":"Interactive effects of molecular, therapeutic, and patient factors on outcome of diffuse low-grade glioma","volume":"41","author":"Hervey-Jumper","year":"2023","journal-title":"J Clin Oncol."},{"issue":"5","key":"2026021901464894500_CIT0011","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2967\/jnumed.122.264859","article-title":"Amino acid PET in neurooncology","volume":"64","author":"Galldiks","year":"2023","journal-title":"J Nucl Med."},{"issue":"1","key":"2026021901464894500_CIT0012","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","article-title":"PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol."},{"issue":"8","key":"2026021901464894500_CIT0013","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"3","key":"2026021901464894500_CIT0014","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00415-025-12923-6","article-title":"Clinical characteristics, molecular reclassification trajectories and DNA methylation patterns of long- and short-term survivors of WHO grade II and III glioma","volume":"272","author":"Mair","year":"2025","journal-title":"J Neurol."},{"issue":"3","key":"2026021901464894500_CIT0015","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.apradiso.2004.07.006","article-title":"New aspects on the preparation of [11C]Methionine--a simple and fast online approach without preparative HPLC","volume":"62","author":"Mitterhauser","year":"2005","journal-title":"Appl Radiat Isot."},{"issue":"3","key":"2026021901464894500_CIT0016","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00259-018-4207-9","article-title":"Joint EANM\/EANO\/RANO practice guidelines\/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0","volume":"46","author":"Law","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1","key":"2026021901464894500_CIT0017","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13550-017-0295-y","article-title":"Towards standardization of 18F-FET PET imaging: do we need a consistent method of background activity assessment","volume":"7","author":"Unterrainer","year":"2017","journal-title":"EJNMMI Res"},{"issue":"5","key":"2026021901464894500_CIT0018","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/s41591-025-03633-7","article-title":"RANO criteria for response assessment of brain metastases based on amino acid PET imaging","volume":"31","author":"Albert","year":"2025","journal-title":"Nat Med."},{"issue":"33","key":"2026021901464894500_CIT0019","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults","volume":"41","author":"Wen","year":"2023","journal-title":"J Clin Oncol."},{"issue":"4","key":"2026021901464894500_CIT0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0895-4356(00)00314-0","article-title":"Adjusting for multiple testing - when and how","volume":"54","author":"Bender","year":"2001","journal-title":"J Clin Epidemiol."},{"issue":"4","key":"2026021901464894500_CIT0021","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2967\/jnumed.106.037895","article-title":"Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma","volume":"48","author":"Floeth","year":"2007","journal-title":"J Nucl Med."},{"issue":"11","key":"2026021901464894500_CIT0022","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2967\/jnumed.111.102533","article-title":"11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI","volume":"53","author":"Singhal","year":"2012","journal-title":"J Nucl Med."},{"issue":"9","key":"2026021901464894500_CIT0023","first-page":"5117","article-title":"The role of PET [18F]FDOPA in evaluating low-grade glioma","volume":"35","author":"Villani","year":"2015","journal-title":"Anticancer Res."},{"issue":"1","key":"2026021901464894500_CIT0024","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3174\/ajnr.A4460","article-title":"Diagnostic and prognostic value of 11C-methionine PET for nonenhancing gliomas","volume":"37","author":"Takano","year":"2016","journal-title":"AJNR Am J Neuroradiol."},{"issue":"3","key":"2026021901464894500_CIT0025","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/neuonc\/nox177","article-title":"Visual and semiquantitative 11C-methionine PET: an independent prognostic factor for survival of newly diagnosed and treatment-na\u00efve gliomas","volume":"20","author":"Poetsch","year":"2018","journal-title":"Neuro Oncol"},{"issue":"2","key":"2026021901464894500_CIT0026","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11060-018-2877-6","article-title":"18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-na\u00efve gliomas: a cross-sectional study","volume":"139","author":"Patel","year":"2018","journal-title":"J Neurooncol."},{"issue":"6","key":"2026021901464894500_CIT0027","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1007\/s11307-019-01357-y","article-title":"Prognostic Value of O-(2-[18F]Fluoroethyl)-L-Tyrosine PET\/CT in newly diagnosed WHO 2016 Grade II and III Glioma","volume":"21","author":"Kertels","year":"2019","journal-title":"Mol Imaging Biol."},{"issue":"5","key":"2026021901464894500_CIT0028","doi-asserted-by":"crossref","first-page":"e19017","DOI":"10.1097\/MD.0000000000019017","article-title":"Prognostic value of 18F-FET PET\/CT in newly diagnosed WHO 2016 high-grade glioma","volume":"99","author":"Dissaux","year":"2020","journal-title":"Medicine (Baltim)."},{"issue":"1","key":"2026021901464894500_CIT0029","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41598-021-04216-5","article-title":"Maximum 11C-methionine PET uptake as a prognostic imaging biomarker for newly diagnosed and untreated astrocytic glioma","volume":"12","author":"Nakajo","year":"2022","journal-title":"Sci Rep."},{"issue":"9","key":"2026021901464894500_CIT0030","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/neuonc\/noac040","article-title":"Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas","volume":"24","author":"Ninatti","year":"2022","journal-title":"Neuro Oncol"},{"issue":"3","key":"2026021901464894500_CIT0031","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol."},{"key":"2026021901464894500_CIT0032","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) - Central Nervous System Cancers, Version 1.2025","author":"National Comprehensive Cancer Network (NCCN)","year":"2025"},{"issue":"4","key":"2026021901464894500_CIT0033","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00401-015-1398-z","article-title":"IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas","volume":"129","author":"Olar","year":"2015","journal-title":"Acta Neuropathol."},{"issue":"5","key":"2026021901464894500_CIT0034","doi-asserted-by":"crossref","first-page":"e13233","DOI":"10.1111\/bpa.13233","article-title":"Refinement of prognostication for IDH -mutant astrocytomas using DNA methylation-based classification","volume":"34","author":"Kling","year":"2024","journal-title":"Brain Pathol."},{"issue":"11","key":"2026021901464894500_CIT0035","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1093\/jnen\/nlz082","article-title":"Mitotic index thresholds do not predict clinical outcome for IDH-Mutant astrocytoma","volume":"78","author":"Yoda","year":"2019","journal-title":"J Neuropathol Exp Neurol."},{"issue":"7","key":"2026021901464894500_CIT0036","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/(SICI)1097-0142(19970401)79:7<1381::AID-CNCR16>3.0.CO;2-W","article-title":"Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas","volume":"79","author":"Coons","year":"1997","journal-title":"Cancer."},{"issue":"3","key":"2026021901464894500_CIT0037","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00401-010-0725-7","article-title":"Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician\u2019s perspective","volume":"120","author":"van den Bent","year":"2010","journal-title":"Acta Neuropathol."},{"issue":"1","key":"2026021901464894500_CIT0038","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00401-024-02811-0","article-title":"Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma","volume":"148","author":"Ghisai","year":"2024","journal-title":"Acta Neuropathol."},{"issue":"10","key":"2026021901464894500_CIT0039","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.2967\/jnumed.110.078592","article-title":"Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas","volume":"51","author":"Fueger","year":"2010","journal-title":"J Nucl Med."},{"issue":"3","key":"2026021901464894500_CIT0040","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/neuonc\/nov148","article-title":"Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis","volume":"18","author":"Dunet","year":"2016","journal-title":"Neuro Oncol"},{"issue":"3","key":"2026021901464894500_CIT0041","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/1754-9485.13322","article-title":"18 F-FET PET maximum standard uptake value and WHO tumour classification grade in glioma","volume":"66","author":"Tatkovic","year":"2022","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"1","key":"2026021901464894500_CIT0042","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/neuonc\/nox176","article-title":"The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis","volume":"20","author":"Wijnenga","year":"2018","journal-title":"Neuro-Oncology."},{"issue":"5","key":"2026021901464894500_CIT0043","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3171\/2019.6.JNS19972","article-title":"Contemporary assessment of extent of resection in molecularly defined categories of diffuse low-grade glioma: a volumetric analysis","volume":"133","author":"Kavouridis","year":"2020","journal-title":"J Neurosurg."},{"issue":"2","key":"2026021901464894500_CIT0044","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.radonc.2011.03.006","article-title":"Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy","volume":"99","author":"Piroth","year":"2011","journal-title":"Radiother Oncol."},{"issue":"7","key":"2026021901464894500_CIT0045","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0000000000001262","article-title":"Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM","volume":"84","author":"Suchorska","year":"2015","journal-title":"Neurology."},{"issue":"8","key":"2026021901464894500_CIT0046","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1007\/s00259-019-04337-0","article-title":"Re-evaluation of the diagnostic performance of 11C-methionine PET\/CT according to the 2016 WHO classification of cerebral gliomas","volume":"46","author":"Kim","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"2","key":"2026021901464894500_CIT0047","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11060-010-0117-9","article-title":"Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas","volume":"99","author":"Okubo","year":"2010","journal-title":"J Neurooncol."},{"issue":"8","key":"2026021901464894500_CIT0048","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2967\/jnumed.112.103069","article-title":"Transport of 3-fluoro-L-\u03b1-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET","volume":"53","author":"Wiriyasermkul","year":"2012","journal-title":"J Nucl Med."},{"issue":"1","key":"2026021901464894500_CIT0049","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-012-0986-1","article-title":"The role of LAT1 in (18)F-DOPA uptake in malignant gliomas","volume":"111","author":"Youland","year":"2013","journal-title":"J Neurooncol."},{"issue":"15_suppl","key":"2026021901464894500_CIT0050","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1200\/JCO.2019.37.15_suppl.2000","article-title":"Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p\/19q codeletion","volume":"37","author":"Van Den Bent","year":"2019","journal-title":"J Clin Oncol."},{"issue":"23","key":"2026021901464894500_CIT0051","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1200\/JCO.21.02543","article-title":"Joint final report of EORTC 26951 and RTOG 9402: phase III trials with procarbazine, lomustine, and vincristine chemotherapy for anaplastic oligodendroglial tumors","volume":"40","author":"Lassman","year":"2022","journal-title":"J Clin Oncol."},{"issue":"3","key":"2026021901464894500_CIT0052","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.24.00049","article-title":"Survival outcomes associated with first-line procarbazine, CCNU, and vincristine or temozolomide in combination with radiotherapy in IDH-Mutant 1p\/19q-Codeleted Grade 3 Oligodendroglioma","volume":"43","author":"Kacimi","year":"2025","journal-title":"J Clin Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaf196\/64136641\/noaf196.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaf196\/64136641\/noaf196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaf196\/64136641\/noaf196.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:46:57Z","timestamp":1771483617000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/27\/12\/3292\/8241205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":52,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,8,23]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaf196","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,8,23]]}}}